Related Experiment Video
Updated: Jun 28, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Vigilance Needed in Treating a Child with Disseminated TB: A Case Report
Hemasri Velmurugan1, Krishnapriya Neelambaram1, Meenalotchini Prakash Gurunthalingam1
1Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Drug-induced liver injury (DILI) can occur during anti-tuberculosis therapy for disseminated tuberculosis. Careful monitoring of liver enzymes is crucial in pediatric patients undergoing treatment for tuberculosis to prevent severe complications.
Area of Science:
- Pediatric Infectious Diseases
- Hepatology
- Pharmacovigilance
Background:
- Tuberculosis remains a leading cause of infection-related mortality globally.
- Disseminated tuberculosis, a severe form, arises from Mycobacterium tuberculosis spread.
- First-line anti-tuberculosis drugs (isoniazid, rifampicin, pyrazinamide) are associated with hepatotoxicity.
Observation:
- A case of drug-induced liver injury (DILI) is presented in a one-year-old child with disseminated tuberculosis.
- The child received a fixed-dose combination of anti-tuberculosis therapy (ATT) including isoniazid, rifampicin, and pyrazinamide.
- Initial liver parameters were normal, but a rapid increase in liver enzymes indicated liver injury during treatment.
Findings:
- Causality assessment scales confirmed the association between anti-tuberculosis therapy and liver injury.
- Diagnosis of tuberculosis in children is challenging due to non-specific symptoms.
- Prompt diagnosis and treatment of disseminated TB are vital to prevent drug resistance.
Implications:
- Close monitoring for ATT-induced DILI is essential in pediatric patients.
- Effective management of disseminated tuberculosis is critical to avoid poor prognosis and limited treatment options.
- Highlighting the importance of vigilant monitoring in pediatric tuberculosis management.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

